The net effect is it delays the generic products from coming on the market, and the impact, of course, is that you have to pay the higher prices for much longer. On some of the large-selling drugs, you're looking at tens of millions of dollars in a Manitoba drug program, and they will not get the savings from the generics for possibly two or more years longer.
Regarding the ability to put unrelated patents on a list at Health Canada and keep generics off, the Supreme Court said you shouldn't be able to do that. We thought that was the law, and the provinces were basing their estimates on that. Now all of that is being changed.